FDA approves Amgen’s Repatha for heart attack and stroke prevention
In a significant advancement for cardiovascular disease management, Amgen's Repatha (evolocumab) has received approval from the U.S. Food and Drug Administration (FDA) to prevent heart ... Read More
FDA approves ViiV Healthcare’s Juluca for maintenance treatment of HIV-1
ViiV Healthcare, a joint venture between GlaxoSmithKline (GSK), Pfizer, and Shionogi, has received approval from the U.S. Food and Drug Administration (FDA) for its two-drug ... Read More
FDA grants accelerated approval to AstraZeneca’s Calquence for mantle cell lymphoma treatment
AstraZeneca has achieved a significant milestone with the early FDA approval of Calquence (acalabrutinib) for the treatment of adult patients with mantle cell lymphoma who ... Read More
FDA grants approval to Yescarta for treatment of certain types of lymphoma
In a significant development for lymphoma treatment, Kite Pharma, a subsidiary of Gilead Sciences, has received approval from the U.S. Food and Drug Administration (FDA) ... Read More
Lupin expands US women’s health portfolio with $150m acquisition of Symbiomix Therapeutics
Lupin Limited, a Mumbai-based generics pharmaceutical company, has strategically broadened its foothold in the women’s health sector by acquiring Symbiomix Therapeutics. The acquisition, valued at ... Read More
Spark Therapeutics’ Luxturna nears FDA approval for gene therapy treating inherited blindness
In a significant development in gene therapy, Spark Therapeutics' Luxturna (voretigene neparvovec) is on the verge of receiving FDA approval for treating blindness caused by ... Read More
Novo Nordisk’s Fiasp gains FDA approval for fast-acting insulin, enhancing diabetes management in US
Novo Nordisk, a leading Danish pharmaceutical company, has secured a significant regulatory milestone with the US FDA approval of its innovative fast-acting mealtime insulin aspart ... Read More
FDA approves Eli Lilly’s Verzenio for metastatic breast cancer treatment
Eli Lilly and Company (Lilly) has announced receiving U.S. Food and Drug Administration (FDA) approval for Verzenio (abemaciclib), to treat patients with metastatic breast cancer ... Read More
FDA approves Novo Nordisk’s Victoza for cardiovascular disease treatment in type 2 diabetes patients
Novo Nordisk’s diabetes medication, Victoza (liraglutide), has gained U.S. Food and Drug Administration (FDA) approval for an expanded use, marking a significant step forward in ... Read More
FDA approves Novo Nordisk’s Victoza for heart disease treatment in type 2 diabetes patients
In a significant advancement for diabetes care, Danish pharmaceutical giant Novo Nordisk has received approval from the U.S. Food and Drug Administration (FDA) to use ... Read More